Trial · NCT06687265
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | effect of metformin versus placebo during 28 days on HVPG, in patients with cirrhosis and a HVPG ≥ 12 mm Hg already treated with carvedilol. | after 28 days of treatment | HVPG measures before and after metformin or placebo treatment |
| Secondary | the rate of patients with a clinically significant improvement in HVPG | after 28 days of treatment | Change in arterial pressure after treatment : HVPG \> or = 12 mm Hg, or at least a 10% reduction from baseline, |
| Secondary | Change in cirrhosis severity MELD score | after 28 days of treatment | MELD (Model for End-Stage Liver Disease) score classification (6-40 with high score is worse outcome) |
| Secondary | Change in cirrhosis severity Child-Pugh score | after 28 days of treatment | Child-Pugh classification or Child-Turcotte-Pugh classification (5-15 with high score is worse outcome) |
| Secondary | change in systemic haemodynamics | after 28 days of treatment | The size (diameter) of a blood vessel. |
| Secondary | the tolerability of metformin in patients with cirrhosis and a HVPG ≥ 12 mm Hg | after 28 days of treatment | treatment compliance |
| Secondary | Maximum metformin plasma level | after 28 days of treatment | plasma level (at 2h30 of last dose) |
| Secondary | Relative changes in HVPG | day 28 | HVPG measure |
| Secondary | Change in arterial pressure | after 28 days of treatment | HVGP |
| Secondary | the safety of metformin in patients with cirrhosis and a HVPG ≥ 12 mm Hg | 30 days after the beginning of treatment | complication and adverse event evaluate by CTCAE guideline during treatment |
| Secondary | Change in liver steatosis | after 28 days of treatment | Controlled Attenuation Parameter with FibroScan® |
| Secondary | Change in markers of systemic inflammation | after 28 days of treatment. | |
| Secondary | Change in markers of hepatocyte stress | after 28 days of treatment | hepatocyte large extracellular vesicles |
| Secondary | Change in markers of endothelial function | after 28 days of treatment | |
| Secondary | Change in platelet count | after 28 days of treatment | |
| Secondary | Change in liver stiffness by VCTE | after 28 days of treatment | using FibroScan® |
| Secondary | Change in liver stiffness by 2D-shear wave elastography | after 28 days of treatment | using Aixplorer® |
| Secondary | Change in SPLEEN stiffness by VCTE | after 28 days of treatment | using FibroScan® |
| Secondary | Change in spleen stiffness by 2D-shear wave elastography | after 28 days of treatment | using Aixplorer® |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06687265/registered